Division of Tumor Genetics B030, German Cancer Research Center, Heidelberg, Germany.
Cancer Res. 2012 Dec 1;72(23):6079-88. doi: 10.1158/0008-5472.CAN-12-2230. Epub 2012 Nov 20.
A broad range of human malignancies is associated with nonrandom 1p36 deletions, suggesting the existence of tumor suppressors encoded in this region. Evidence for tumor-specific inactivation of 1p36 genes in the classic "two-hit" manner is scarce; however, many tumor suppressors do not require complete inactivation but contribute to tumorigenesis by partial impairment. We discuss recent data derived from both human tumors and functional cancer models indicating that the 1p36 genes CHD5, CAMTA1, KIF1B, CASZ1, and miR-34a contribute to cancer development when reduced in dosage by genomic copy number loss or other mechanisms. We explore potential interactions among these candidates and propose a model where heterozygous 1p36 deletion impairs oncosuppressive pathways via simultaneous downregulation of several dosage-dependent tumor suppressor genes.
广泛的人类恶性肿瘤与非随机的 1p36 缺失有关,这表明该区域存在肿瘤抑制基因。尽管存在肿瘤特异性失活 1p36 基因的经典“双打击”方式的证据很少,但许多肿瘤抑制基因并不需要完全失活,而是通过部分损伤促进肿瘤发生。我们讨论了最近从人类肿瘤和功能癌症模型中获得的数据,这些数据表明,当基因组拷贝数缺失或其他机制导致 1p36 基因 CHD5、CAMTA1、KIF1B、CASZ1 和 miR-34a 的剂量减少时,这些基因会促进癌症的发展。我们探索了这些候选基因之间的潜在相互作用,并提出了一个模型,其中杂合性 1p36 缺失通过同时下调几个剂量依赖性肿瘤抑制基因来损害抗肿瘤通路。